JCR Pharmaceuticals Co., Ltd.
JCRRF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $86 | $59 | $7,192 | $9,223 |
| % Growth | 45.4% | -99.2% | -22% | – |
| Cost of Goods Sold | $14 | $17 | $4,326 | $2,677 |
| Gross Profit | $73 | $43 | $2,866 | $6,546 |
| % Margin | 84.3% | 72.1% | 39.8% | 71% |
| R&D Expenses | $30 | $23 | $15,431 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $23 | $6,818 | $6,669 | $6,561 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$6,794 | -$13,338 | $0 |
| Operating Expenses | $53 | $47 | $8,762 | $6,561 |
| Operating Income | $20 | -$4 | -$5,896 | -$15 |
| % Margin | 23% | -7.5% | -82% | -0.2% |
| Other Income/Exp. Net | $2 | -$1 | -$199 | $253 |
| Pre-Tax Income | $22 | -$5 | -$6,095 | $238 |
| Tax Expense | $7 | -$1 | $1,878 | $36 |
| Net Income | $15 | -$546 | -$4,183 | $115 |
| % Margin | 17.6% | -918.3% | -58.2% | 1.2% |
| EPS | 0.13 | -4.48 | -34.28 | 0.93 |
| % Growth | 102.9% | 86.9% | -3,786% | – |
| EPS Diluted | 0.13 | -4.48 | -34.28 | 0.93 |
| Weighted Avg Shares Out | 122 | 122 | 122 | 123 |
| Weighted Avg Shares Out Dil | 122 | 122 | 122 | 122 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $17 | $30 | $0 |
| Depreciation & Amortization | $5 | $844 | $844 | $799 |
| EBITDA | $28 | $200 | -$5,101 | $739 |
| % Margin | 32% | 335.5% | -70.9% | 8% |